Aclarion (ACON) Competitors $7.48 +0.04 (+0.47%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$7.64 +0.15 (+2.00%) As of 09/12/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, BGLC, SSY, ATIP, DHAC, NIVF, OTRK, BACK, BTTX, and UPHLShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), SunLink Health Systems (SSY), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), Ontrak (OTRK), IMAC (BACK), Better Therapeutics (BTTX), and UpHealth (UPHL). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Biorestorative Therapies BioNexus Gene Lab SunLink Health Systems ATI Physical Therapy Digital Health Acquisition NewGenIvf Group Ontrak IMAC Better Therapeutics UpHealth Aclarion (NASDAQ:ACON) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends. Which has stronger earnings & valuation, ACON or BRTX? Aclarion has higher earnings, but lower revenue than Biorestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclarion$50K86.83-$6.99MN/AN/ABiorestorative Therapies$605.20K20.30-$8.98M-$1.27-1.21 Do analysts recommend ACON or BRTX? Aclarion presently has a consensus target price of $11,758.50, suggesting a potential upside of 156,994.19%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Biorestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biorestorative Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to ACON or BRTX? In the previous week, Aclarion and Aclarion both had 1 articles in the media. Biorestorative Therapies' average media sentiment score of 1.91 beat Aclarion's score of 1.89 indicating that Biorestorative Therapies is being referred to more favorably in the news media. Company Overall Sentiment Aclarion Very Positive Biorestorative Therapies Very Positive Which has more volatility and risk, ACON or BRTX? Aclarion has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500. Is ACON or BRTX more profitable? Biorestorative Therapies has a net margin of -1,772.40% compared to Aclarion's net margin of -11,238.59%. Aclarion's return on equity of -83.63% beat Biorestorative Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Aclarion-11,238.59% -83.63% -76.55% Biorestorative Therapies -1,772.40%-137.00%-88.31% Do institutionals and insiders have more ownership in ACON or BRTX? 7.5% of Aclarion shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 30.8% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAclarion beats Biorestorative Therapies on 7 of the 12 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34M$7.66B$5.85B$10.14BDividend YieldN/A2.76%5.68%4.60%P/E RatioN/A75.5875.3425.98Price / Sales86.8342.18514.54181.13Price / CashN/A24.1437.5660.44Price / Book0.157.3512.156.29Net Income-$6.99M$242.04M$3.29B$271.07M7 Day Performance4.89%1.60%0.74%3.87%1 Month Performance5.57%0.28%4.82%4.88%1 Year Performance-99.56%16.28%60.58%26.12% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.5731 of 5 stars$7.49+0.5%$11,758.50+156,994.2%-99.6%$4.34M$50K0.007Positive NewsBRTXBiorestorative Therapies2.3847 of 5 stars$1.84+0.6%N/A+2.7%$14.68M$400K-1.457Positive NewsHigh Trading VolumeBGLCBioNexus Gene Lab0.6298 of 5 stars$5.68-1.6%N/A+39.6%$10.20M$9.51M0.0030Positive NewsSSYSunLink Health SystemsN/A$1.12+16.6%N/A+49.2%$7.88M$31.09M4.661,376Gap UpATIPATI Physical TherapyN/A$0.68flatN/A-88.5%$2.98M$741.86M-0.045,600DHACDigital Health AcquisitionN/A$0.60-22.1%N/A-57.3%$2.16MN/A0.002,021News CoverageGap DownHigh Trading VolumeNIVFNewGenIvf GroupN/A$1.88flatN/A-99.7%$1.63M$5.43M0.00N/APositive NewsOTRKOntrak2.9538 of 5 stars$0.07-14.8%$3.00+4,043.6%-99.3%$305K$10.18M0.00250News CoveragePositive NewsShort Interest ↓BACKIMACN/A$0.07+4.7%N/A-93.5%$152K$72.05K0.00180Positive NewsBTTXBetter TherapeuticsN/A$0.00flatN/AN/A$5KN/A0.0040UPHLUpHealthN/A$0.00flatN/A-99.9%$4K$130M0.001,750 Related Companies and Tools Related Companies Biorestorative Therapies Competitors BioNexus Gene Lab Competitors SunLink Health Systems Competitors ATI Physical Therapy Competitors Digital Health Acquisition Competitors NewGenIvf Group Competitors Ontrak Competitors IMAC Competitors Better Therapeutics Competitors UpHealth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACON Stock Alerts